MedTrace Logo

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

NCT03817840 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2024-06-04

No results posted yet for this study

Summary

This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and metabolism that accompany them. The study is designed to determine if the high cortisol and AgRP levels in the blood of people living with Cushing's syndrome, either from taking steroid medications or from tumors, impact body fat and metabolism by turning off brown fat, which is a type of fat that increases one's metabolism.

Conditions

Interventions

PROCEDURE

Treatment of Cushing's

Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism

Sponsors & Collaborators

  • New York Obesity and Nutrition Research Center

    collaborator OTHER

  • Columbia University

    lead OTHER

Principal Investigators

  • Gabrielle Page-Wilson, MD · Columbia University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2021-07-01
Completion
2021-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03817840 on ClinicalTrials.gov